it went public on 2 February 2016, with an IPO that raised $94 million. Similarly, When did beam Therapeutics go...
ntla stock
Out of 16 analysts, 7 (43.75%) are recommending NTLA as a Strong Buy, 7 (43.75%) are recommending NTLA as a...
The Regeneron deal includes work in hemophilia A and B, while Intellia has pipeline projects underway in hereditary angioedema, acute...
